The Pfizer/BioNTech COVID-19 vaccine has been shown to be safe and highly effective in young children aged 5 to 11 years.
Monday, September 20, the company will seek U.S. approval for the shot to be used in children in this age group as soon as possible. Pfizer developed the vaccine jointly with its German partner BioNTech.
A lower dose of the Pfizer-BioNTech coronavirus vaccine — one-third the amount given to adults and teens — is safe and triggered a robust immune response in children as young as 5 years old.
The finding, eagerly anticipated by many parents and pediatricians, is a crucial step toward the two-shot coronavirus vaccine regimen becoming available for younger school-aged children, perhaps close to Halloween. Last month, the U.S. FDA, gave full approval to the Pfizer-BioNTech vaccine to be used in all individuals over the age of 16. The vaccine has also been available for emergency use for people 12 to 15 years old.